Biotech | October 11, 2021
Astra’s antibody injection trial indicates it can prevent and treat Covid-19
AZD7442 reduced risk of developing severe Covid-19 or death in Tackle Phase III outpatient treatment trial
AZD7442 reduced risk of developing severe Covid-19 or death in Tackle Phase III outpatient treatment trial
At present 18 per cent of the local pharmaceutical market is under government's price control
Implementation of the system to provide faster, seamless and hassle-free healthcare solutions
Filing for WHO Emergency Use Authorisation this month
It is designed to tackle mental health issues
ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses
The COVID Working Group has recommended extension of the gap between the first and second doses of Covishield
BBIL had proposed to carry out Phase II/III clinical trial of Covaxin in the age group of 2 to 18 years
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
Vivimed strategy is to increase its share of Branded products in CIS Markets.
Subscribe To Our Newsletter & Stay Updated
